Ann Arbor-based Esperion Therapeutics, Inc. has reportedly completed a $33-million preferred stock financing that CEO Tim Mayleben said will allow the clinical-stage biopharmaceutical company “to continue to advance our novel lead product candidate, ETC-1002, for which we have 100 percent worldwide rights, in multiple ongoing and planned Phase 2 clinical trials.” Esperion is developing small molecule therapies for statin-intolerant patients with elevated levels of low-density lipoprotein cholesterol (LDL-C). ETC-1002, an oral LDL-C lowering medication taken once daily, has apparently “been well tolerated and not associated with serious side effects.” See Esperion Therapetuics Press Release, April 26, 2013.